AB&B BIO-TECH-B's Huierkangxin® is the only vaccine selected for the preliminary review list of innovative drugs under the national medical insurance
I'm PortAI, I can summarize articles.
AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine HuiErKangXin® has been included in the preliminary review list of innovative drugs for the national medical insurance. This vaccine received new drug application approval in May 2023 and is suitable for individuals aged three and above, aiming to provide protection against H1N1, H3N2, and two types of influenza B viruses. The vaccine has undergone significant upgrades based on traditional vaccines, offering advantages such as high purity and low risk of adverse reactions
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments